Journal
JOURNAL OF OSTEOPOROSIS
Volume 2010, Issue -, Pages -Publisher
HINDAWI LTD
DOI: 10.4061/2010/941419
Keywords
-
Categories
Ask authors/readers for more resources
The striking clinical benefits of intermittent parathyroid hormone in osteoporosis have begun a new era of skeletal anabolic agents. One potential new agent is monoclonal antibody to sclerostin, a potent inhibitor of osteoblastogenesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
